<?xml version="1.0" encoding="UTF-8"?>
<p>Participants were recruited for the 
 <italic>ZINC HIV</italic> trial between October 2013 and June 2015 from clinical HIV and addiction care sites, non-clinical sites and snowball recruitment to participate in a double-blinded randomized controlled trial in St. Petersburg, Russia to assess the efficacy of zinc supplementation vs. placebo on HIV morbidity [
 <xref rid="pone.0218852.ref024" ref-type="bibr">24</xref>]. This study recruited 254 individuals who met the following eligibility criteria: 1) age 18 to 70 years old; 2) HIV-seropositive; 3) provided information for at least two contacts; 4) had a stable address within St. Petersburg or districts within 100 kilometers of the city; 5) possessed a home or a mobile phone; 6) had recent history of heavy alcohol consumption (i.e., National Institute on Alcohol Abuse and Alcoholism [NIAAA] risky drinking criteria: &gt; 4 standard drinks in a day [or &gt; 14 standard drinks/week] for men and &gt; 3/day [or 7/week] for women); and 7) were anti-retroviral treatment (ART) na√Øve at the time of enrollment. Participants were excluded if they were not fluent in Russian; had a cognitive impairment resulting in inability to provide informed consent; or were breastfeeding or pregnant. Not all individuals in the randomized controlled trial were HCV-infected. For the current cross-sectional analysis, we included eligible participants who also had a positive qualitative HCV RNA test at baseline.
</p>
